SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-035749
Filing Date
2020-06-10
Accepted
2020-06-10 21:16:11
Documents
2
Period of Report
2020-06-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3909
2 POA DOCUMENT poa.txt EX-24.4_921396 3635
  Complete submission text file 0001209191-20-035749.txt   8937
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address
Tsai Benjamin (Reporting) CIK: 0001791247 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39112 | Film No.: 20956016